Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
3.040
+0.120 (4.11%)
At close: Jun 26, 2026, 4:00 PM EDT
3.030
-0.010 (-0.35%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Cabaletta Bio Employees
As of December 31, 2025, Cabaletta Bio had 156 total employees, including 156 full-time and 2 part-time employees. The number of employees decreased by 8 or -4.88% compared to the previous year.
Employees
156
Change (1Y)
-8
Growth (1Y)
-4.88%
Revenue / Employee
n/a
Profits / Employee
-$1,110,304
Market Cap
495.69M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| REGENXBIO | 371 |
| Arvinas | 246 |
| Sutro Biopharma | 133 |
| Neurogene | 131 |
| Ocugen | 116 |
| C4 Therapeutics | 104 |
| Assembly Biosciences | 73 |
CABA News
- 19 days ago - Cabaletta Bio Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 24 days ago - Cabaletta Bio presents new data for rese-cel in autoimmune diseases - TheFly
- 24 days ago - Cabaletta Bio Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 24 days ago - Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress - GlobeNewsWire
- 24 days ago - Cabaletta Bio Slides: Corporate presentation - Filings
- 26 days ago - Cabaletta Bio Proxy statement: Proxy filing - Filings
- 5 weeks ago - Cabaletta Bio Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 6 weeks ago - Cabaletta Bio presents new clinical data for rese-cel - TheFly